The expression and clinical significance of melanoma‑associated antigen‑A1, ‑A3 and ‑A11 in glioma

Guo,Liru; Sang,Meixiang; Liu,Qingrui; Fan,Xiaojie; Zhang,Xiao; Shan,Baoen

doi:10.3892/ol.2013.1351

The expression and clinical significance of melanoma‑associated antigen‑A1, ‑A3 and ‑A11 in glioma

Authors:
- Liru Guo
- Meixiang Sang
- Qingrui Liu
- Xiaojie Fan
- Xiao Zhang
- Baoen Shan
View Affiliations

Affiliations: Department of Neurology, The Fourth Clinical Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Research Center, The Fourth Clinical Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Tumor Research Institute, The Fourth Clinical Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
Published online on: May 15, 2013 https://doi.org/10.3892/ol.2013.1351
Pages: 55-62

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Melanoma‑associated antigens (MAGEs) were initially identified in melanoma and have since been widely studied. Melanoma‑associated antigen‑As (MAGE‑As), a subfamily of MAGEs, are expressed in germ cells and various types of cancer, and are considered to be ideal targets for cancer immunotherapy. Glial cells and melanocytes originate from the neural ectoderm, so tumors derived from these two types of cells, i.e. gliomas and melanomas, may have common biological characteristics. However, studies on the expression of the MAGE‑A family in gliomas are limited and conflicting. In the present study, the expression levels of MAGE‑A1, ‑A3 and ‑A11 were detected by immunohistochemistry, and the association of their expression levels with the clinicopathological parameters, overall survival (OS) and ki‑67 labeling indices of glioma patients were analyzed. The results showed that i) the expression levels of MAGE‑A1, ‑A3 and ‑A11 proteins in the glioma tissues were 64.1, 51.3 and 57.7%, respectively and that no MAGE‑A1, ‑A3 or ‑A11 expression was detected in the normal brain specimens; ii) the expression levels of MAGE‑A1 and ‑A11 increased with ascending pathological grades and were positively correlated with the ki‑67 labeling index; and iii) the OS of the patients in the groups with high MAGE‑A1 (P=0.005) and ‑A11 (P=0.019) expression was statistically lower compared with the groups with low expression and no significant differences in OS were detected between the patients in the groups with high and low MAGE‑A3 expression (P=0.304). Based on these results, we conclude that MAGE‑A1, ‑A3 and ‑A11 may be used as ideal targets for glioma immunotherapy, and that MAGE‑A1 and ‑A11 expression may be involved in tumor cell proliferation. These proteins may be potential indicators of a poor prognosis in glioma patients.

View Figures

View References

1.	Parney IF, Hao C and Petruk KC: Glioma immunology and immunotherapy. Neurosurgery. 46:778–792. 2000.PubMed/NCBI
2.	Surawicz TS, Davis F, Freels S, Laws ER Jr and Menck HR: Brain tumor survival: results from the National Cancer Data Base. J Neurooncol. 40:151–160. 1998. View Article : Google Scholar : PubMed/NCBI
3.	Scanlan MJ, Gure AO, Jungbluth AA, Old LJ and Chen YT: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
4.	Scanlan MJ, Simpson AJ and Old LJ: The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 4:12004.PubMed/NCBI
5.	Zendman AJ, Ruiter DJ and Van Muijen GN: Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol. 194:272–288. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 5:615–625. 2005. View Article : Google Scholar : PubMed/NCBI
7.	Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T and Lucas S: An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61:5544–5551. 2001.PubMed/NCBI
8.	Sang M, Wang L, Ding C, et al: Melanoma-associated antigen genes - an update. Cancer Lett. 302:85–90. 2011. View Article : Google Scholar : PubMed/NCBI
9.	De Plaen E, Arden K, Traversari C, et al: Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics. 40:360–369. 1994.PubMed/NCBI
10.	Rogner UC, Wilke K, Steck E, Korn B and Poustka A: The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics. 29:725–731. 1995. View Article : Google Scholar : PubMed/NCBI
11.	van der Bruggen P, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1643–1647. 1991.
12.	Kuramoto T: Detection of MAGE-1 tumor antigen in brain tumor. Kurume Med J. 44:43–51. 1997. View Article : Google Scholar : PubMed/NCBI
13.	Bodey B, Siegel SE and Kaiser HE: MAGE-1, a cancer/testis-antigen, expression in childhood astrocytomas as an indicator of tumor progression. In Vivo. 16:583–588. 2002.PubMed/NCBI
14.	Syed ON, Mandigo CE, Killory BD, Canoll P and Bruce JN: Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma. J Clin Neurosci. 19:1016–1021. 2012. View Article : Google Scholar : PubMed/NCBI
15.	Kleihues P, Louis DN, Scheithauer BW, et al: The WHO classification of tumours of the nervous system. JNeuropathol Exp Neurol. 61:215–225. 2002.
16.	Matos LL, Stabenow E, Tavares MR, Ferraz AR, Capelozzi VL and Pinhal MA: Immunohistochemistry quantification by a digital computer-assisted method compared to semiquantitative analysis. Clinics (Sao Paulo). 61:417–424. 2006. View Article : Google Scholar
17.	Wild PJ, Kunz-Schughart LA, Stoehr R, et al: High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol. 27:385–391. 2005.PubMed/NCBI
18.	Ries J, Mollaoglu N, Toyoshima T, et al: A novel multiple-marker method for the early diagnosis of oral squamous cell carcinoma. Dis Markers. 27:75–84. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Jang SJ, Soria JC, Wang L, et al: Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res. 61:7959–7963. 2001.PubMed/NCBI
20.	Bergeron A, Picard V, LaRue H, et al: High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer. 125:1365–1371. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Matković B, Juretić A, Spagnoli GC, et al: Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study. Croat Med J. 52:171–177. 2011.PubMed/NCBI
22.	Jacobs JF, Grauer OM, Brasseur F, et al: Selective cancer-germline gene expression in pediatric brain tumors. J Neurooncol. 88:273–280. 2008. View Article : Google Scholar : PubMed/NCBI
23.	Chi DD, Merchant RE, Rand R, et al: Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol. 150:2143–2152. 1997.PubMed/NCBI
24.	Sahin U, Türeci O, Schmitt H, et al: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 92:11810–11813. 1995. View Article : Google Scholar : PubMed/NCBI
25.	Saikali S, Avril T, Collet B, et al: Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol. 81:139–148. 2007. View Article : Google Scholar : PubMed/NCBI
26.	Lian Y, Sang M, Ding C, et al: Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: a retrospective clinical study. J Cancer Res Clin Oncol. 138:519–527. 2012. View Article : Google Scholar : PubMed/NCBI
27.	Bu N, Wu H, Sun B, et al: Exosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with glioma. J Neurooncol. 104:659–667. 2011.PubMed/NCBI
28.	Phuphanich S, Wheeler CJ, Rudnick JD, et al: Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 62:125–135. 2012. View Article : Google Scholar : PubMed/NCBI
29.	Schvartzman JM, Sotillo R and Benezra R: Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer. 10:102–115. 2010. View Article : Google Scholar : PubMed/NCBI
30.	Weigel MT and Dowsett M: Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 17:R245–R262. 2010. View Article : Google Scholar : PubMed/NCBI
31.	Rao CV, Yamada HY, Yao Y and Dai W: Enhanced genomic instabilities caused by deregulated microtubule dynamics and chromosome segregation: a perspective from genetic studies in mice. Carcinogenesis. 30:1469–1474. 2009. View Article : Google Scholar : PubMed/NCBI
32.	Yoshida Y, Nakada M, Harada T, et al: The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. J Neurooncol. 98:41–47. 2010. View Article : Google Scholar : PubMed/NCBI
33.	Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
34.	Torp SH: Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies. Clin Neuropathol. 21:252–257. 2002.PubMed/NCBI
35.	Johannessen AL and Torp SH: The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res. 12:143–147. 2006. View Article : Google Scholar : PubMed/NCBI
36.	Paulus W: GFAP, Ki67 and IDH1: perhaps the golden triad of glioma immunohistochemistry. Acta Neuropathol. 118:603–604. 2009. View Article : Google Scholar : PubMed/NCBI
37.	Xia LP, Xu M, Chen Y and Shao WW: Expression of MAGE-A11 in breast cancer tissues and its effects on the proliferation of breast cancer cells. Mol Med Rep. 7:254–258. 2012.PubMed/NCBI
38.	Grau E, Oltra S, Martínez F, et al: MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors. J Cancer Res Clin Oncol. 135:523–531. 2009. View Article : Google Scholar : PubMed/NCBI
39.	Dellaretti M, Reyns N, Touzet G, et al: Diffuse brainstem glioma: prognostic factors. J Neurosurg. 117:810–814. 2012. View Article : Google Scholar : PubMed/NCBI